{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"1"},{"groupId":"OG007","value":"5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"10"}],"units":"Participants"}],"description":"Objective Disease Control Rate (ODCR) was defined as the percentage of subjects with a Best Overall Response of Complete Response (CR; disappearance of all target lesions, any pathological lymph nodes whether target or non-target must have reduction in short axis to \\<10mm), Partial Response (PR; at least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum of diameters), or Stable Disease (neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify as Progressive Disease) as assessed by the Investigator per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1)","groups":[{"description":"300mg DKN-01 monotherapy in recurrent EEC. DKN-01 administered by IV infusion.","id":"OG000","title":"DKN-01 Monotherapy in Recurrent EEC"},{"description":"300mg DKN-01+paclitaxel in recurrent EEC. DKN-01 and paclitaxel administered by IV infusion.","id":"OG001","title":"DKN-01 + Paclitaxel in Recurrent EEC"},{"description":"300mg DKN-01 monotherapy in recurrent EOC. DKN-01 administered by IV infusion.","id":"OG002","title":"DKN-01 Monotherapy in Recurrent EOC"},{"description":"300mg DKN-01+paclitaxel in recurrent EOC. DKN-01 and paclitaxel administered by IV infusion.","id":"OG003","title":"DKN-01 + Paclitaxel in Recurrent EOC"},{"description":"300mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.","id":"OG004","title":"DKN-01 300mg Monotherapy in Carcinosarcoma"},{"description":"600mg DKN-01 monotherapy in carcinosarcoma. DKN-01 administered by IV infusion.","id":"OG005","title":"DKN-01 600mg Monotherapy in Carcinosarcoma"},{"description":"300mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.","id":"OG006","title":"DKN-01 300mg + Paclitaxel in Carcinosarcoma"},{"description":"600mg DKN-01 + paclitaxel in carcinosarcoma. DKN-01 and paclitaxel administered by IV infusion.","id":"OG007","title":"DKN-01 600mg + Paclitaxel in Carcinosarcoma"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Evaluable Analysis Set (EAS), all subjects who received any amount of DKN-01 and had at least 1 evaluated post-baseline RECIST assessment or were discontinued due to death.","reportingStatus":"POSTED","timeFrame":"Baseline to study completion (approximately 6 months)","title":"Number of Subjects With Objective Disease Control Rate (ODCR) in Patients With Recurrent EEC or EOC or Carcinosarcoma (MMMT).","type":"SECONDARY","unitOfMeasure":"Participants"}